Increased plasma platelet-activating factor in children with acute asthmatic attacks and decreased in vivo and in vitro production of platelet-activating factor after immunotherapy
View abstract on PubMed
Summary
This summary is machine-generated.Platelet-activating factor (PAF) is elevated in asthma patients, especially during attacks. Successful immunotherapy reduces PAF levels, suggesting its role in asthma development.
Area Of Science
- Immunology
- Respiratory Medicine
- Biochemistry
Background
- Investigating the role of platelet-activating factor (PAF) in bronchial asthma pathogenesis.
- Assessing circulating PAF levels and in vitro PAF production.
Purpose Of The Study
- To determine if PAF is involved in the development of asthma.
- To compare PAF levels in asthmatic patients and healthy controls.
- To evaluate the effect of immunotherapy on PAF levels.
Main Methods
- Radioimmunoassay kits used to measure PAF.
- Studied children with acute asthma, newly diagnosed asthma, immunotherapy responders/non-responders, and healthy controls.
- Assessed spontaneous and stimulated PAF production in vitro.
Main Results
- Elevated circulating PAF in new asthma patients compared to controls (p < 0.005).
- Circulating PAF decreased with successful immunotherapy in good responders.
- Marked increase in PAF during acute asthmatic attacks (up to 20x controls).
- Increased spontaneous and stimulated PAF production in new patients, normalizing post-immunotherapy (p < 0.005).
Conclusions
- Elevated PAF during acute asthma attacks and normalization post-immunotherapy suggest PAF's involvement in asthma pathogenesis.
- Enhanced in vivo and in vitro PAF production supports PAF's role in asthma development.